Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer

摘要: Trastuzumab (Herceptin®) is a humanized monoclonal antibody that binds selectively to human epidermal growth factor 2 (HER2), interfering with its downstream cancer-promoting effects. This article focuses on the efficacy and tolerability of trastuzumab in HER2-positive advanced gastric cancer. The potential as cytotoxic for use cancer was confirmed by vitro studies cell lines xenograft models. In randomized, controlled, open-label, multinational trial patients cancer, plus chemotherapy (cisplatin capecitabine or 5-fluorouracil) significantly more efficacious than alone, terms longer median overall survival (13.8 vs. 11.1 months alone group) [primary endpoint], progression-free survival, higher response rate. across patient subgroups, although stronger effects were observed subgroup high HER2 overexpression (immunohistochemistry 2+/fluorescence in-situ hybridization positive immunohistochemistry 3+). There slightly burden group based small between-group numerical differences rates common gastrointestinal general adverse events. Most individual events reported this at grade 1 level severity. However, both treatment groups approximately half haematological 3 4 severity, no marked differences. combination cisplatin fluoropyrimidine an effective regimen has acceptable represents important advance